original ) (raw )Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis
Julius Spicak
Scandinavian journal of gastroenterology, 2016
View PDFchevron_right
Pharmacogénétique de l’infliximab dans la maladie de Crohn
Vinciane Dideberg
Acta Endoscopica, 2007
View PDFchevron_right
Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center
Ferenc Nagy
Expert opinion on biological therapy, 2017
View PDFchevron_right
Efficacy And Safety Of The Biosimilar Infliximab CT-P13 Treatment In Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort
Ferenc Nagy
Journal of Crohn's and Colitis, 2015
View PDFchevron_right
The duration of effect of infliximab maintenance treatment in paediatric Crohn’s disease is limited
Lissy Ridder
Alimentary Pharmacology & Therapeutics, 2010
View PDFchevron_right
Need for infliximab dose intensification in Crohn's disease and ulcerative colitis
Enrique Rey
World journal of gastroenterology : WJG, 2014
View PDFchevron_right
Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response
Luis Abreu
Gastroenterología y hepatología
View PDFchevron_right
Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease
Nicolas Williet
Inflammatory Bowel Diseases, 2017
View PDFchevron_right
Infliximab in pediatric ulcerative colitis: Two year follow up
Robert Baldassano
Gastroenterology, 2003
View PDFchevron_right
Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers
Antonio Tursi
Annals of Gastroenterology, 2019
View PDFchevron_right
Review and clinical perspectives for the use of infliximab in ulcerative colitis
Craig Render , Hillary Steinhart , L. Dieleman
Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2008
View PDFchevron_right
Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice
Antonio Tursi
European review for medical and pharmacological sciences, 2010
View PDFchevron_right
Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)
Ahmed Shelbaya
Advances in Therapy
View PDFchevron_right
Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update
Garrett Lawlor
Clinical and Experimental Gastroenterology, 2009
View PDFchevron_right
The efficacy, tolerability and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn’s disease
Grażyna Rydzewska
Polish Archives of Internal Medicine
View PDFchevron_right
Clinical Experience with Infliximab for Crohn’s Disease: The First 100 Patients in Edmonton, Alberta
Mang Ma
Canadian Journal of Gastroenterology, 2002
View PDFchevron_right
Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13
ByoungOh Kwon
Expert review of gastroenterology & hepatology, 2015
View PDFchevron_right
An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease
Ahmed Faisal
International Journal of Colorectal Disease
View PDFchevron_right
Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania
Letiţia Tugui , Cristina Toader , Carmen Preda
Romanian Journal of Gastroenterology, 2003
View PDFchevron_right